Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samer Al Hadidi

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Journal of Cancer Policy|May 16, 2024
Authorship characteristics of hematology and oncology education chapters: A comprehensive analysisHeba Altarawneh, Mohammad Manasrah, Yasemin Al Shanableh, et al.
JAMA Network Open|November 10, 2023
Adverse Event Reporting in Randomized Clinical Trials for Multiple MyelomaMimi Najjar, John McCarron, Edward R Scheffer Cliff, et al.
Haematologica|February 5, 2026
Second primary malignancy in multiple myeloma: does a prior malignancy matter?Alissa Visram, Hsien Seow, Rajeshkar Chakraborty, et al.
Journal of Cancer Policy|December 7, 2023
Use of subjective minimizing language at hematology and oncology conferences: A systematic reviewAbdel-Azez Abusamak, Mohammad Abusamak, Mohammed Al-Abbadi, et al.
Archives of Pathology & Laboratory Medicine|July 2, 2024
Navigating the 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic LanguageHadil Zureigat, Bridget Adcock, Daniel P Nurse, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Blood Cancer Journal|March 31, 2026
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patientsHira Cheema, Asis Shrestha, Syed Naqvi, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
Journal of the National Cancer Institute|November 9, 2025
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trialsMaria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, et al.
Clinical Hematology International|September 30, 2024
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaTanvi H Patel, Ramya Bachu, Trilok Shrivastava, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Journal of Cancer Policy|May 16, 2024
Authorship characteristics of hematology and oncology education chapters: A comprehensive analysisHeba Altarawneh, Mohammad Manasrah, Yasemin Al Shanableh, et al.
JAMA Network Open|November 10, 2023
Adverse Event Reporting in Randomized Clinical Trials for Multiple MyelomaMimi Najjar, John McCarron, Edward R Scheffer Cliff, et al.
Haematologica|February 5, 2026
Second primary malignancy in multiple myeloma: does a prior malignancy matter?Alissa Visram, Hsien Seow, Rajeshkar Chakraborty, et al.
Journal of Cancer Policy|December 7, 2023
Use of subjective minimizing language at hematology and oncology conferences: A systematic reviewAbdel-Azez Abusamak, Mohammad Abusamak, Mohammed Al-Abbadi, et al.
Archives of Pathology & Laboratory Medicine|July 2, 2024
Navigating the 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic LanguageHadil Zureigat, Bridget Adcock, Daniel P Nurse, et al.
Cancer|June 7, 2023
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myelomaMeera Mohan, Zimu Gong, Timothy Cody Ashby, et al.
Blood Cancer Journal|March 31, 2026
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patientsHira Cheema, Asis Shrestha, Syed Naqvi, et al.
Blood Advances|July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imagingCarolina Schinke, Leo Rasche, Cody Ashby, et al.
Journal of the National Cancer Institute|November 9, 2025
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trialsMaria Mainou, Muatassem Alsadhan, Kalliopi Tsapa, et al.
Clinical Hematology International|September 30, 2024
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaTanvi H Patel, Ramya Bachu, Trilok Shrivastava, et al.
Pageof 10